溶血磷脂酰胆碱酰基转移酶1在肿瘤中作用的研究进展

doi:10.16352/j.issn.1001-6325.2024.02.0256

基础医学与临床 ›› 2024, Vol. 44 ›› Issue (2): 256-259.doi: 10.16352/j.issn.1001-6325.2024.02.0256

溶血磷脂酰胆碱酰基转移酶1在肿瘤中作用的研究进展

陈雪¹, 罗添^2,3, 魏超君^2,3*

1.甘肃中医药大学公共卫生学院,甘肃兰州 730000;甘肃省人民医院
2.国家卫生健康委胃肠肿瘤诊治重点实验室;
3.临床研究与转化医学研究所,甘肃兰州 730000

收稿日期:2023-08-17 修回日期:2023-10-09 发布日期:2024-02-05
通讯作者: ^*weichaojun-GSPH@hotmail.com
基金资助:
甘肃省自然科学基金(22JR5RA500);甘肃省人民医院院内科研基金(21GSSYA-1)

Advances in the role of lysophosphatidyl-choline acyltransferase 1 in tumors

CHEN Xue¹, LUO Tian^2,3, WEI Chaojun^2,3*

1. School of Public Health, Gansu University of Chinese Medicine, Lanzhou 730000;
2. National Health Commission Key Laboratory of Diagnosis and Therapy of Gastrointestinal Tumor;
3. the Institute of Clinical Research and Translational Medicine, Gansu Provincial Hospital, Lanzhou 730000,China

Received:2023-08-17 Revised:2023-10-09 Published:2024-02-05
Contact: ^*weichaojun-GSPH@hotmail.com

摘要/Abstract

摘要： 溶血磷脂酰胆碱酰基转移酶1作为磷脂胆碱代谢途径中的关键代谢酶,可通过脱酰基-再酰化来介导磷脂酰胆碱的合成,使细胞膜磷脂组成成分发生改变,导致细胞膜骨架发生重塑。溶血磷脂酰胆碱酰基转移酶1可通过加速肿瘤细胞膜磷脂成分的改变、或与表皮生长因子受体、细胞周期相关等肿瘤驱动基因相互作用影响肿瘤细胞的增殖、迁移和侵袭,以及肿瘤细胞的耐药性,促进肿瘤的发展。

关键词: 溶血磷脂酰胆碱酰基转移酶1, 磷脂胆碱代谢, 磷脂, 肿瘤

Abstract: Lysophosphatidylcholine acyltransferase 1(LPCAT1), a key metabolic enzyme in the phosphatidyl-choline metabolism pathway, mediates phosphatidylcholine synthesis through deacylation-reacylation, which leads to alterations in the phospholipids composition of cell membranes and the remodelling of the cellular cytoskeleton. Lysophosphatidylcholine acyltransferase 1 has been shown to be highly expressed in gastric, breast and colorectal cancer, and can accelerate the alteration of the phospholipids composition of tumor cell membranes or interact with tumor driver genes, such as epidermal growth factor receptor and cell cycle-related genes. It might promote tumor development by affecting tumor cell proliferation, migration, invasion and resistance to chemotherapy.

Key words: lysophosphatidylcholine acyltransferase 1(LPCAT1), phosphatidylcholine metabolism, phospholipids, tumor

中图分类号:

R730.23

陈雪, 罗添, 魏超君. 溶血磷脂酰胆碱酰基转移酶1在肿瘤中作用的研究进展[J]. 基础医学与临床, 2024, 44(2): 256-259.

CHEN Xue, LUO Tian, WEI Chaojun. Advances in the role of lysophosphatidyl-choline acyltransferase 1 in tumors[J]. Basic & Clinical Medicine, 2024, 44(2): 256-259.

参考文献

[1]Balleza D, Alessandrini A, Beltrán García MJ. Role of lipid composition, physicochemical interactions, and membrane mechanics in the molecular actions of microbial cyclic lipopeptides[J]. J Membr Biol, 2019, 252:131-157.
[2]Johnson AA, Stolzing A. The role of lipid metabolism in aging, lifespan regulation, and age-related disease[J]. Aging cell, 2019, 18:e13048. doi: 10.1111/acel.13048.
[3]Butnor KJ. Controversies and challenges in the histologic subtyping of lung adenocarcinoma[J]. Transl Lung Cancer Res, 2020, 9:839-846.
[4]Szlasa W, Zendran I, Zalesińska A, et al. Lipid composition of the cancer cell membrane[J]. J Bioenerg Biomembr, 2020, 52:321-342.
[5]Chen ZX, Liang L, Huang HQ, et al. LPCAT1 enhances the invasion and migration in gastric cancer: based on computational biology methods and in vitro experiments[J]. Cancer Med, 2023,12:13438-13454.
[6]Bi J, Ichu TA, Zanca C, et al. Oncogene amplification in growth factor signaling pathways renders cancers depend-ent on membrane lipid remodeling[J]. Cell Metab, 2019, 30:525-538.e8.
[7]Ji W, Peng Z, Sun B, et al. Lpcat1 promotes malignant transformation of hepatocellular carcinoma cells by directly suppressing STAT1[J]. Front Oncol, 2021, 11:678714.doi: 10.3389/fonc.2021.678714.
[8]Liu Y, Yang C, Zhang Z, et al. Gut microbiota dysbiosis accelerates prostate cancer progression through increased LPCAT1 expression and enhanced DNA repair pathways[J]. Front Oncol, 2021, 11:679712.doi: 10.3389/fonc.2021.679712.
[9]Oliver GR, Marcano-Bonilla S, Quist J, et al. LPCAT1-TERT fusions are uniquely recurrent in epithelioid trophoblastic tumors and positively regulate cell growth[J]. PLoS One, 2021, 16:e0250518.doi: 10.1371/journal.pone.0250518.
[10]Tao M, Luo J, Gu T, et al. LPCAT1 reprogramming cholesterol metabolism promotes the progression of esophageal squamous cell carcinoma[J]. Cell Death Dis, 2021, 12:845. doi: 10.1038/s41419-021-04132-6.
[11]Shen L, Gu P, Qiu C, et al. Lysophosphatidylcholine acyltransferase 1 promotes epithelial-mesenchymal transi-tion of hepatocellular carcinoma via the Wnt/β-catenin signaling pathway[J]. Ann Hepatol, 2022, 27:100680. doi: 10.1016/j.aohep.2022.100680.
[12]Liu R, Yin C, Zhao P, et al. Nuclear respiratory factor 1 drives hepatocellular carcinoma progression by forming a positive feedback loop with LPCAT1-ERK1/2-CREB axis[J]. Biol Direct, 2023,18:67. doi: 10.1186/s13062-023-00428-z.
[13]Wei C, Dong X, Lu H, et al. LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating PI3K/AKT/MYC pathway[J]. Clin Cancer Res, 2019, 38:95. doi: 10.1186/s13046-019-1092-4.
[14]Zhao T, Sun R, Ma X, et al. Overexpression of LPCAT1 enhances endometrial cancer stemness and metastasis by changing lipid components and activating the TGF/β-Smad2/3 signaling pathway[J]. Acta Biochim Biophys Sin (Shanghai), 2022, 54:904-916.
[15]Ding J, Ding X, Leng Z. LPCAT1 promotes gefitinib resistance via upregulation of the EGFR/PI3K/AKT signal-ing pathway in lung adenocarcinoma[J]. J Cancer, 2022, 13:1837-1847.
[16]Jun Y, Tang Z, Luo C, et al. Leukocyte-mediated combined targeted chemo and gene therapy for esophageal cancer[J]. ACS Appl Mater Interfaces, 2020, 12:47330-47341.
[17]Zhang H, Zheng Y. LPCAT1 is transcriptionally regulated by FOXA1 to promote breast cancer progression and paclitaxel resistance[J]. Oncol Lett, 2023, 25:134.doi: 10.3892/ol.2023.13720.

溶血磷脂酰胆碱酰基转移酶1在肿瘤中作用的研究进展

Advances in the role of lysophosphatidyl-choline acyltransferase 1 in tumors

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	郭健宏, 王亚玲, 崔文光. 脂蛋白相关磷脂酶A2在急性冠状动脉综合征中作用的研究进展[J]. 基础医学与临床, 2024, 44(1): 103-107.
[2]	吴国嘏, 翟书杰, 孙笑, 黄怡然, 李咏梅, 孙丽. 羟酰辅酶A脱氢酶在癌中作用机制的研究进展[J]. 基础医学与临床, 2024, 44(1): 119-123.
[3]	吴念平, 黄惠利, 周快乐, 周策凡, 唐景峰. PTTG1在肿瘤发病机制中作用的研究进展[J]. 基础医学与临床, 2023, 43(9): 1448-1452.
[4]	王继辉, 曹吉烈, 张立军, 张军, 鹿文葆. TARBP2降解AKAP12转录本促进人乳腺癌细胞转移[J]. 基础医学与临床, 2023, 43(8): 1259-1264.
[5]	邹宇祥, 唐慧. TLR2在消化道肿瘤发生发展中作用的研究进展[J]. 基础医学与临床, 2023, 43(8): 1304-1308.
[6]	陈忠婕, 黄嘉如, 胡清, 赵珍琴, 陈俏俏, 孙浚源, 贾静. 免疫检查点CD276蛋白参与肿瘤发生发展作用机制的研究进展[J]. 基础医学与临床, 2023, 43(7): 1143-1147.
[7]	杜风, 陈翌阳, 张楠, 徐俊玄, 宁婷婷, 朱圣韬, 张澍田. FOXL2NB在结直肠癌中的表达和临床意义[J]. 基础医学与临床, 2023, 43(6): 909-915.
[8]	张海灵, 杨玉, 周倩倩, 汪远金, 王婷. 微囊藻毒素-LR处理的中性粒细胞NETs促进结直肠癌细胞迁移[J]. 基础医学与临床, 2023, 43(6): 967-973.
[9]	李珍, 段昭君, 罗云萍. 神经节苷脂GD2可作为肺癌干细胞一个潜在的候选标志物[J]. 基础医学与临床, 2023, 43(5): 777-784.
[10]	高欣, 于永波, 王海存, 姜兴明, 王志东. 环状RNA核受体相互作用蛋白1对肿瘤发生发展的调控机制研究进展[J]. 基础医学与临床, 2023, 43(5): 827-832.
[11]	徐倩, 段华, 甘露, 刘麒薇. RhoGTP酶活化蛋白在上皮细胞间质转化中作用的研究进展[J]. 基础医学与临床, 2023, 43(2): 301-305.
[12]	谭树芬, 杨谢兰, 杨琳琳, 李树清. 紫杉醇联合卡铂化疗对卵巢癌VEGF及肿瘤标志物表达的影响[J]. 基础医学与临床, 2023, 43(12): 1861-1865.
[13]	李岩, 王雅楠, 张亮, 田翠丽, 赵建华. 两种麻醉方式对经尿道膀胱肿瘤电切术患者闭孔神经反射和术后恢复的影响[J]. 基础医学与临床, 2023, 43(12): 1857-1860.
[14]	贾楠, 檀厚睿, 严毅飞, 何仲, 姚顺宇, 王颖轶. 北京协和医学院“精准治疗下的肿瘤学”课程教学实践[J]. 基础医学与临床, 2023, 43(12): 1896-1900.
[15]	马郏俊延, 芮天楠, 张永胜. 血小板反应蛋白2在恶性肿瘤中作用的研究进展[J]. 基础医学与临床, 2023, 43(12): 1881-1885.